@article{ATM16543,
author = {Rebecca Feldman and Edward S. Kim},
title = {Prognostic and predictive biomarkers post curative intent therapy},
journal = {Annals of Translational Medicine},
volume = {5},
number = {18},
year = {2017},
keywords = {},
abstract = {Large-scale screening trials have demonstrated that early diagnosis of lung cancer results in a significant reduction in lung cancer mortality. Despite improvements in detecting more lung cancers at early stages, the 5-year survival rates of lung cancers diagnosed before widespread disease is only 30–50%. High rates of recurrence, despite early diagnosis, suggest the need to improve treatment strategies based on the likelihood of recurrence in patient subsets, as well as explore the role of predictive markers for therapy selection in the adjuvant setting. In the era of personalized medicine, there have been a wide array of molecular alterations and signatures studied for their potential prognostic and predictive utility, however most have failed to translate into clinical tools. This review will discuss progress made in clinical management of lung cancer, and recent progress in the development of patient selection tools for the refinement of early stage lung cancers.},
issn = {2305-5847}, url = {https://atm.amegroups.org/article/view/16543}
}